Faron Pharma Share News (FARN)

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans

(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.

TRADING UPDATES: Armadale Capital eyes Mahenge project financing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

Faron discloses events of default on debt obligations to lender

(Alliance News) - Faron Pharmaceuticals Ltd shares fell on Monday, after it said it is in breach of several undertakings agreed in a secured debt deal with lender IPF Fund II SCA, SICAV-FIAR.

TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Faron launches second phase of leukaemia treatment trial

(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.

Faron says first patient dosed in phase two Bexmab trial for cancer

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial.

Faron unveils promising antibody study results

(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on Monday.

Faron Pharmaceuticals hails positive results of cancer drug trial

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said results from a probe of a cancer drug were promising.

IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilimab have been published in Cell Reports Medicine, an open-access journal. According to the trial, bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumours. It also showed that CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects, and that bexmarilimab induced macrophage activation and increased IFNy signalling in patients who achieved disease control and prolonged survival.

Faron publishes cancer immunotherapy study findings

(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised monoclonal anti-CLEVER-1 antibody aimed at transforming the landscape of anticancer immunotherapies.

IN BRIEF: Faron Pharmaceuticals starts Phase 2 of Bexmab trial

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts.

Faron reveals details of next stage of bexmarilimab study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study investigating bexmarilimab in combination with standard of care, would focus on hypomethylating agents (HMAs)-refractory or relapsed myelodysplastic syndromes (MDS).